SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00092391
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this study is to determine the mumps virus strength at the end of shelf-life
(expiration date) of an approved vaccine.
NCT00092391 Measles Mumps Rubella Varicella
2 Interventions
Name: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live
Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0
Type: Biological
Group Labels: 3 Control Group Mumps Expiry Group 1 Mumps Expiry Group 2
Name: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Description: 0.5 mL subcutaneous injection on Day 0
Type: Biological
Group Labels: 3 Control Group Mumps Expiry Group 1 Mumps Expiry Group 2
Primary Outcomes
Measure: Neutralizing antibodies to mumps at 6 weeks postvaccination Time: 6 weeks postvaccination
Secondary Outcomes
Measure: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination Time: 6 weeks and 1 year postvaccination
Purpose: Prevention
Allocation: Randomized
Single Group Assignment
There is one SNP
SNPs
A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
The purpose of this study is to determine the mumps virus strength at the end of shelf-life
(expiration date) of an approved vaccine. --- V205C ---
HPO Nodes